What Ebrantil Retard Treats: Main Uses and Benefits

Ebrantil retard is used for the long-term therapeutic management of chronic high blood pressure, specifically essential hypertension and certain forms of secondary hypertension. As an antihypertensive agent, the medication is used to address sustained systemic pressure overload and may assist with maintaining consistency in elevated systolic and diastolic blood pressure readings.

The prolonged-release nature of the capsule contributes to supporting all-day blood pressure lowering, which helps reduce the constant strain on the heart and blood vessels associated with the chronic disease state. Clinical settings in which this medicine is considered relevant include sustained moderate to severe high blood pressure, including situations of refractory hypertension and in patients whose hypertension is complicated by Type 2 Diabetes Mellitus or dyslipidemias. The core benefit is providing support that helps ease the overall pressure load and assists with maintaining functional stability when managing this chronic condition. Supporting consistent blood pressure management throughout the day may contribute to easing the long-term load on the cardiovascular system.

---

Quick Fact: Management of Systemic Pressure Overload

Benefit Domain	Clinical Context	Support Provided
Symptom Management	Chronic Arterial Hypertension	Helps ease the overall strain on the circulatory system.
Symptom Stabilization	Elevated Systolic and Diastolic readings	May assist with maintaining consistent blood pressure lowering.
Patient Relevance	Hypertension with Type 2 Diabetes	Is considered relevant in contexts involving Type 2 Diabetes.

Ebrantil retard eligibility is strictly defined by regulatory authorities based on population-specific data and known risks. Use of the prolonged-release capsules is officially established for adults managing essential hypertension. The medicine is contraindicated and must not be used by patients with a known hypersensitivity to Urapidil or any component of the formulation. Absolute prohibitions also apply to patients with specific mechanical circulatory conditions, including aortic isthmus stenosis (coarctation of the aorta) and certain arteriovenous shunts.

Eligibility is strictly limited for other populations. Use in children and adolescents (under 18 years) is not established because regulatory data confirming safety and efficacy are currently insufficient. The medicine is not recommended for women who are pregnant or breastfeeding due to a lack of adequate human data. Conditional eligibility applies to older adults, where treatment must begin with the smallest dose, and to patients with moderate to severe hepatic or renal function disorders, who require caution and potential dose adjustment.

Interactions with other medicines and products

The official regulatory documents for Ebrantil retard (Urapidil) establish two primary interaction classifications: pharmacodynamic potentiation and specific pharmacokinetic alteration.

---

Pharmacodynamic Potentiation

Antihypertensive Exacerbation: The blood pressure-lowering effect is formally documented to be exacerbated by co-administration of alpha-receptor blockers, vasodilators, and other blood pressure lowering drugs. Other substances listed with potential for potentiation include Baclofen, which can increase the antihypertensive effect.

Specific Risks: The use of Imipramine and Neuroleptics is documented to increase the risk of orthostatic hypotension. Conversely, Corticoids are noted to cause a decrease in the antihypertensive effect due to hydro sodium retention.

Substance and Condition Notes: The antihypertensive action is also formally documented to be exacerbated by alcohol and by specific patient conditions such as hypovolaemia (e.g., from vomiting or diarrhea).

---

Pharmacokinetic and Exposure Alteration

One specific pharmacokinetic interaction is documented: Cimetidine inhibits the metabolism of Urapidil, which regulatory documents state results in a 15% increase in Urapidil serum concentration. No timing-based separation rules or formal interaction-based contraindicated combinations are explicitly listed in the regulatory profile.

How Ebrantil retard Works

Urapidil's mechanism produces a reduction in systemic pressure through a dual mechanism of action, targeting distinct regulatory components in the periphery and the central nervous system to influence central and peripheral regulatory components.

---

Peripheral alpha1-Adrenoceptor Blockade

This domain focuses on the molecular action at the blood vessels. Urapidil acts as a competitive antagonist at the postsynaptic alpha1-adrenoceptors on vascular smooth muscle cells. This interaction prevents the binding of the natural signaling molecule norepinephrine, thereby interrupting the intracellular cascade that causes muscle contraction. The resulting relaxation of resistance arterioles (vasodilation) induces a reduction in the Total Peripheral Resistance (TPR), altering the systemic pressure load on the circulatory system.

---

Central 5 -HT1 A Receptor Agonism

This domain addresses the drug's effect on central signaling. Urapidil also functions as an agonist at the 5 -HT1 A serotonin receptors in the brainstem, which are critical centers for cardiovascular regulation. Activation of these receptors suppresses the excitatory sympathetic outflow from the central nervous system. This sympathoinhibition influences the body's natural compensatory response, reflex tachycardia. This sympathoinhibition acts as a counter-regulatory mechanism that influences the cardiovascular response to peripheral vasodilation.

How to Use Ebrantil Retard

This section describes the standard administration principles for Ebrantil retard (Urapidil prolonged-release capsules).

---

Administration Scope

The medication is designed for the oral route of administration as a hard capsule, intended for the long-term therapeutic management of chronic high blood pressure. The dosage is typically divided into two administrations daily to ensure consistent Urapidil delivery across a 24-hour period, a requirement of the prolonged-release formulation. The administration should take place after meals, such as following breakfast and supper.

Category	Detail
Route of administration	Oral route
Frequency pattern	Twice daily (divided use)
Timing in relation to meals	Taken after meals (e.g., breakfast and supper)

---

Official Dosing and Handling

The standard dosing regimen for adults involves starting with a low dose, which is then gradually adjusted (titrated) by the clinician to achieve the required response. Doses typically range from 60 mg to 120 mg total daily, though the maximum recommended dose for the prolonged-release capsule formulation is 180 mg total daily.

To preserve the specialized drug delivery mechanism, the capsules must be swallowed whole with water. They must not be chewed, crushed, or opened under any circumstances, as this action compromises the controlled release of the active substance. Furthermore, official guidance states that the dosage may be adjusted according to the age of the patient.

Research evidence / Overview of studies for Ebrantil retard

---

Evidence for use in Chronic High Blood Pressure

Research examining Urapidil prolonged-release was studied for the long-term management of high blood pressure. The evidence is derived from multiple short-term and intermediate-term randomized controlled trials (RCTs) that research examined how blood pressure measurements changed in adults diagnosed with mild to severe hypertension. Studies were also conducted that compared this prolonged-release formulation against an inactive substance (placebo) and against other classes of medication was observed in trials used to manage blood pressure.

Trials monitored outcomes, specifically focusing on measured changes in both the upper (systolic) and lower (diastolic) blood pressure readings. The studies report how outcomes evolved in the observed populations, noting the percentage of patients whose blood pressure measurements were associated with pre-defined targets. Findings describe patterns observed in the studies related to the stability of blood pressure measurements over a 24-hour period, a factor often tracked using specialized monitors.

What remains uncertain is the extent of long-term data for major cardiovascular outcomes. Evidence is generally focused on measuring blood pressure itself, and the long-term data are not fully established regarding the reduction of major cardiovascular outcomes, such as stroke or heart attack. Comparative evidence against all possible newer drug classes is lacking, and results apply only to the populations studied in the trials.

---

Evidence for use in Patients with Co-existing Metabolic Conditions

The prolonged-release formulation was evaluated in hypertensive patients presenting with conditions where symptoms may vary in intensity, such as co-existing Type 2 Diabetes or high cholesterol levels (dyslipidemias). These trials specifically research examined outcomes related to the body's systemic or functional imbalance, tracking changes in specific metabolic markers. Measurements monitored included changes in serum potassium levels, certain cholesterol readings (LDL-cholesterol), and indicators of glucose control.

Research highlights changes measured during the study period for these metabolic outcomes. For instance, some comparative studies data show patterns related to the preservation of a neutral metabolic profile, meaning the changes in glucose and lipid markers was associated with only minimal movement from the starting measurements.

Evidence is limited regarding the long-term meaning of these findings. These studies primarily reflect short-term changes in laboratory values, typically over 8 to 12 weeks. Follow-up durations were limited, and therefore, the certainty remains low regarding whether the observed metabolic profile is associated with long-term cardiovascular outcomes for this specific patient group.

---

Key Limitations and Areas of Research Uncertainty

When reviewing the complete body of evidence, the research highlights what is known and what is still uncertain. The studies consistently contribute to understanding the patterns measured related to blood pressure management. Limited information for long-term outcomes related to event reduction is a known gap, as the majority of highly certain evidence is based on follow-up durations that were limited to weeks or months. Furthermore, evidence quality varies across studies, and the specific findings from comparative trials, where this drug was observed in studies against several other classes of medication, were mixed. Research is ongoing to continually contextualize the long-term safety and effectiveness of all modern antihypertensive treatments.

Common questions about Ebrantil retard (FAQ)

Q: What is the main difference between Ebrantil retard and other common blood pressure medicines?

Official documents describe the active ingredient as having a dual mechanism of action. It works by acting as an alpha-1 adrenergic antagonist on blood vessels, while also acting on certain serotonin receptors in the brain. This combined approach is a feature that distinguishes it from some other types of blood pressure medications.

---

Q: Are there any specific foods or supplements that should be avoided while using Ebrantil retard?

Regulatory information specifically notes that the blood pressure-lowering effect may be exacerbated by alcohol. While the official instructions state the medication should be taken after meals, specific foods or supplements (other than alcohol) are generally not listed as being strictly forbidden in the core prescribing information.

---

Q: Are there different strengths of Ebrantil retard available?

Official product information indicates that the prolonged-release capsules are commonly supplied in several strengths to allow for dosing flexibility. In many regions, strengths of 30 mg, 60 mg, and 90 mg are available.

---

Q: What is the general success rate described in clinical trials for Ebrantil retard?

Studies examined the percentage of patients who achieved specific target blood pressure goals, referred to as the responder rate. Clinical trials for the drug used alone often report this rate to be in the range of approximately 40% to 70% of the observed population.

---

Q: How does the slow-release format of Ebrantil retard work?

The 'retard' designation means it is a specialized prolonged-release capsule, often utilizing a technology like a Multi-Unit Pellet System (MUPS). This system is designed to release the active substance very slowly into the body to help maintain a stable, consistent concentration throughout the day.

---

Q: Why do official documents mention certain foods to be cautious about with Ebrantil retard?

The regulatory guidance for Ebrantil retard specifies that the capsule should be taken after meals. This administrative condition is noted in official documents, often to help optimize the delivery of the active substance or minimize potential stomach upset.

---

Q: Are there genetic or demographic differences noted in how Ebrantil retard works?

Official prescribing information indicates that dosage may need to be adjusted based on certain patient characteristics. For example, the need for a tailored initial dose is noted for the older adult population.

---

Q: How long does it typically take to start feeling the effect of Ebrantil retard?

Pharmacokinetic studies indicate that the highest concentration of the active substance in the blood, which correlates with its peak effect, occurs approximately 4 to 6 hours after the capsule is administered.

---

Q: Does Ebrantil retard have any known interactions with common pain relievers like ibuprofen?

Official drug interaction databases suggest that Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), a class that includes common pain relievers like ibuprofen, may decrease the therapeutic effect of the active substance.

---

Q: Can Ebrantil retard affect a person's sex drive or function?

Official documentation reports that sexual dysfunction has been observed during clinical experience or post-marketing use of the drug. These events may include effects such as a decreased libido or erectile dysfunction.

---

Q: What should be done if I experience a very noticeable side effect from Ebrantil retard?

Regulatory guidance states that patients who experience a side effect are advised to discuss the event with a healthcare provider. Reporting the side effect to the appropriate national drug regulatory agency is also generally encouraged.

---

Q: Can Ebrantil retard be used for high blood pressure caused by specific conditions?

The prolonged-release capsule formulation is formally approved for the management of essential hypertension (high blood pressure with no known cause). However, the intravenous formulation of the active substance has specific uses for hypertensive emergencies, which can include managing conditions like pre-eclampsia or aortic dissection.

---

Q: What is the potential impact of Ebrantil retard on driving or operating machinery?

Official safety information notes that certain side effects, such as dizziness or fatigue, may temporarily impair a patient's ability to drive or safely operate machinery. This caution is particularly relevant when beginning treatment or when alcohol is consumed concurrently.

---

Q: Does Ebrantil retard have a black box warning in the US (FDA) documentation?

Regulatory records indicate that the sustained-release capsule formulation of this medicine is not currently approved by the US Food and Drug Administration (FDA). Therefore, the specialized 'Black Box Warning' status, which is specific to FDA-approved products, is not applicable in the US.

---

Q: Is it true that Ebrantil retard is sometimes used after a heart event?

Clinical literature shows that the intravenous formulation of the active substance is sometimes used for blood pressure control during perioperative hypertension (around surgery) and has been researched in acute care settings, such as following intracerebral hemorrhage.

How to Store and Dispose of Ebrantil retard

This information reflects the official storage and disposal requirements for Ebrantil retard (urapidil prolonged-release capsules) as specified in regulatory labeling.

Official Storage Conditions

Requirement	Details
Temperature	Store at Controlled Room Temperature, typically 20 C to 25 C (below 25 C is often specified).
Protection	Must be protected from light and moisture.
Packaging	Keep the medicine in the original container to maintain stability and protect the prolonged-release dosage form.
Safety	Keep Ebrantil retard out of the reach and sight of children.

Disposal Instructions

Expired or unused Ebrantil retard must be disposed of according to local pharmaceutical-waste regulations. Do not dispose of the medication in household trash or by flushing it down a toilet or sink, as this prevents the product from reaching the sewage system or surface water.